Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia. Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice. Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective. The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts
The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia
Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies
Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents
Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis
An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics
Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods
A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial
Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the cutlass study
The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study
Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
Pragmatic randomised controlled trial of group psychoeducation versus group support in the maintenance of bipolar disorder
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
The efficacy of a new translational treatment for persecutory delusions: study protocol for a randomised controlled trial (The Feeling Safe Study).
The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial
Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
Automated psychological therapy using virtual reality (VR) for patients with persecutory delusions: study protocol for a single-blind parallel-group randomised controlled trial (THRIVE)
Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012
Eye movement desensitization and reprocessing therapy for psychosis (EMDRp): Protocol of a feasibility randomized controlled trial with early intervention service users.
Worldwide antipsychotic drug search intensities: pharmacoepidemological estimations based on Google Trends data.
Comparison of a theoretically driven cognitive therapy (the Feeling Safe Programme) with befriending for the treatment of persistent persecutory delusions: a parallel, single-blind, randomised controlled trial.
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here